Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease
Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease
Ligand Pharmaceuticals的合作伙伴獲得美國FDA批准使用Ohtuvayre治療慢性阻塞性肺疾病。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。